A humble kitchen spice could pack a powerful antiviral punch. Researchers have found that compounds in cardamom seeds can ...

Liver stiffness measurement after success with oral antivirals predicts HCC risk, particularly among patients with advanced chronic liver disease.

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 ...

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has ...

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations ...

The high-risk group includes individuals with underlying immunodeficiency, those at higher risk of severe influenza despite ...

Background:Respiratory viruses, including influenza viruses, respiratory syncytial virus (RSV), coronaviruses, and other emerging zoonotic pathogens, remain ...

Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir ...

The Influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the ...

Background and objectives Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e ...